MYLeukaemia technology

Our Technology

Inside our engineered human bone-marrow avatars, patient-derived leukaemia cells are exposed to protocol-defined, clinically relevant regimens. High-content imaging and flow cytometry quantify ex vivo response patterns - targeting a structured research readout in approximately 72 hours.

In parallel, multiplex proteomics maps signalling crosstalk between tumour, stromal and immune compartments - supporting research into microenvironment-driven resistance, mechanisms of action, biomarkers and rational combination strategies.

Interested in our technology? Contact us to discuss a research or preclinical collaboration.

How it Works

Under approved research protocols, a small peripheral-blood or bone-marrow sample is processed in our central lab. We isolate viable leukaemia cells and introduce them into MYLeukaemia chipset - our bioengineered bone-marrow-avatar research model.

Cells are exposed to protocol-defined treatment regimens. Flow cytometry and imaging quantify ex vivo response patterns and generate a concise research heatmap with quality-control flags.

The resulting research output may include experimental response measurements, quality-control information, protocol details and study-specific observations. It is not a diagnostic report, does not rank treatments for an individual patient and must not be used for patient management or treatment selection at this stage of development.

Turning complex blood-cancer biology into structured functional evidence.

1

> 100,000 leukemic cells are isolated and integrated in a sophisticated MYLeukaemia Organ-on-Chip Chipset

Isolate Live Cells from protocol-defined blood specimens

2

3

Patient-personalized Bone Marrow Research Model

Functional Precision Oncology sensitivity Testing

Drug testing for clinically used drug regimens ID's Leukaemia’ funcional drivers & rank drug sensitivity by FC & other tools.

Patient-derived blasts colonize a 3D, vascularised Organ-on-Chip, recreating the patient’s bone marrow Leukemic niche within 24h.

For Research Use Only. MYLeukaemia is an R&D-stage platform and is not CE-marked as an in vitro diagnostic medical device. It is not intended for diagnosis, patient management or treatment selection at this point of development.

What Makes Our MYLeukaemia Chipset Unique

A streamlined workflow designed to generate structured functional-response data in approximately 72 hours.

72-hour decision support

Unmatched native marrow-like niche bioengineering for clinically relevant, context-aware drug-response readouts.

Human Bone-Marrow avatars

Functional precision (ex vivo)

Functionally tests patient-derived cells beforehand to complement Standard-of-Care diagnostics (cytogenetics, flow, PCR, NGS) for truly personalized therapy choices.

Minimal-burden sampling

Just +5 mL added to routine peripheral or BM draws; no extra procedure.

Clear heatmap, ranked therapy options, QC flags; available clinical trials; in a simple & concise PDF report

Tumour-board-ready outputs

Pilot-ready & IVDR-aware

TRL4 with MVP on multiple AML cell lines; 20-patient pilot next; CE-IVD horizon ~36 months.

MYCancer. All rights reserved. © 2026

Subscribe to our newsletter

No Spam. Just occasional product updates & events.

Policies

Privacy Notice

Terms of use

Cookies policy

For Research Use Only. MYLeukaemia is an R&D-stage bone-marrow-on-chip platform. It is not CE-marked as an in vitro diagnostic medical device and is not intended for diagnosis, clinical assessment, patient management or treatment selection. Any future clinical use is subject to analytical and clinical validation and the applicable regulatory conformity route.